Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie über orales TP-3654 bei Patienten mit Myelofibrose

30. September 2026 aktualisiert von: Sumitomo Pharma America, Inc.

Eine Open-Label-, Dosiseskalations-, Sicherheits-, pharmakokinetische und pharmakodynamische Studie der Phase 1/2 zu oralem TP-3654 bei Patienten mit primärer oder sekundärer Myelofibrose mit mittlerem oder hohem Risiko

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Studienübersicht

Detaillierte Beschreibung

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Studientyp

Interventionell

Einschreibung (Geschätzt)

240

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Adelaide, Australien
        • Rekrutierung
        • Icon Cancer Centre (Ashford Cancer Centre Research)
        • Kontakt:
    • South Australia
      • Adelaide, South Australia, Australien
    • Victoria
      • Box Hill, Victoria, Australien
        • Rekrutierung
        • Eastern Health Box Hill Hospital
        • Kontakt:
          • SMPA Investigative Site
      • Clayton, Victoria, Australien
        • Rekrutierung
        • Monash University
        • Kontakt:
          • SMPA Investigative Site
      • Fitzroy, Victoria, Australien
        • Rekrutierung
        • St Vincent's Hospital Melbourne
        • Kontakt:
          • SMPA Investigative Site
      • Melbourne, Victoria, Australien
        • Rekrutierung
        • Peter McCallum Center
        • Kontakt:
          • SMPA Investigative Site
      • Richmond, Victoria, Australien
        • Rekrutierung
        • Epworth Healthcare
        • Kontakt:
          • SMPA Investigative Site
      • Antwerp, Belgien, 2020
        • Rekrutierung
        • ZNA Cadix
        • Kontakt:
          • SMPA Investigative Site
      • Antwerp, Belgien, 2030
        • Rekrutierung
        • ZNA Middelheim
        • Kontakt:
          • SMPA Investigative Site
      • Ghent, Belgien, 9000
        • Rekrutierung
        • Universitair Ziekenhuis Gent
        • Kontakt:
          • SMPA Investigative Site
      • Liège, Belgien, 4000
        • Rekrutierung
        • CHU de Liege
        • Kontakt:
          • SMPA Investigative Site
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgien, 3000
        • Rekrutierung
        • University Hospitals Leuven
        • Kontakt:
          • SMPA Investigative Site
      • Halle, Deutschland
        • Rekrutierung
        • Universitätsmedizin Halle
        • Kontakt:
          • SMPA Investigative Site
      • Lübeck, Deutschland
        • Rekrutierung
        • Universitätsklinikum Schleswig-Holstein
        • Kontakt:
          • SMPA Investigative Site
      • Amiens, Frankreich, 80054
        • Rekrutierung
        • Centre Hospitalier Universitaire D'Amiens
        • Kontakt:
          • SMPA Investigative Site
      • Angers, Frankreich, 9000
        • Rekrutierung
        • CHU Angers
        • Kontakt:
          • SMPA Investigative Site
      • Lyon, Frankreich, 69495
        • Rekrutierung
        • Centre Hospitalier Lyon Sud
        • Kontakt:
          • SMPA Investigative Site
      • Nice, Frankreich, 06200
        • Rekrutierung
        • Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
        • Kontakt:
          • SMPA Investigative Site
      • Nîmes, Frankreich, 30029
        • Rekrutierung
        • Institut de cancerologie du Gard
        • Kontakt:
          • SMPA Investigative Site
      • Nîmes, Frankreich
        • Rekrutierung
        • Institut de cancerologie du Gard
        • Kontakt:
          • SMPA Investigative Site
      • Paris, Frankreich, 75010
        • Rekrutierung
        • Hospital Saint Louis
        • Kontakt:
          • SMPA Investigative Site
      • Poitiers, Frankreich, 86021
        • Rekrutierung
        • University Hospital of Poitiers
        • Kontakt:
          • SMPA Investigative Site
      • Villejuif, Frankreich, 94805
        • Rekrutierung
        • Institut Gustave Roussy
        • Kontakt:
          • SMPA Investigative Site
      • Alessandria, Italien, 15121
        • Rekrutierung
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
        • Kontakt:
          • SMPA Investigative Site
      • Aviano, Italien, 33081
        • Rekrutierung
        • Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
      • Bologna, Italien, 40138
        • Rekrutierung
        • IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
        • Kontakt:
          • SMPA Investigative Site
      • Brescia, Italien
        • Rekrutierung
        • ASST - Spedali Civili di Brescia
        • Kontakt:
          • SMPA Investigative Site
      • Meldola, Italien, 47014
        • Rekrutierung
        • IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
        • Kontakt:
          • SMPA Investigative Site
      • Milan, Italien, 20122
        • Rekrutierung
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Kontakt:
          • SMPA Investigative Site
      • Torino, Italien, 10126
        • Rekrutierung
        • Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
        • Kontakt:
          • SMPA Investigative Site
      • Aichi, Japan
      • Aomori, Japan
        • Rekrutierung
        • Aomori Prefectural Central Hospital
        • Kontakt:
      • Chiba, Japan
        • Rekrutierung
        • National Cancer Center Hospital East
        • Kontakt:
      • Fukuoka, Japan
      • Hokkaido, Japan
        • Rekrutierung
        • Hokkaido University Hospital
        • Kontakt:
      • Kamakura, Japan, 247-8533
      • Miyazaki, Japan
      • Okayama, Japan
        • Rekrutierung
        • Okayama University Hospital
        • Kontakt:
      • Osaka, Japan
        • Rekrutierung
        • The University of Osaka Hospital
        • Kontakt:
          • Michiko Ichii, MD
          • Telefonnummer: 06-6879-5111
      • Saitama, Japan
        • Abgeschlossen
        • Saitama Medical Center
      • Sendai, Japan
        • Rekrutierung
        • Tohoku University Hospital
        • Kontakt:
          • Noriko Fukuhara, MD
          • Telefonnummer: 022-717-7000
      • Shizuoka, Japan
        • Abgeschlossen
        • Shizuoka Cancer Center
      • Tokyo, Japan, 160-0023
        • Rekrutierung
        • Tokyo Medical University Hospital
        • Kontakt:
      • Tokyo, Japan
        • Rekrutierung
        • Juntendo University Hospital
        • Kontakt:
      • Tokyo, Japan, 179-0072
        • Rekrutierung
        • Nerima Hikarigaoka Hospital
        • Kontakt:
      • Tsu, Japan
    • Alberta
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6T 1Z3
        • Rekrutierung
        • University of British Columbia
        • Kontakt:
          • SMPA Investigative Site
      • Vancouver, British Columbia, Kanada, V6T 1Z3
        • Rekrutierung
        • St. Paul's Hospital Hematology/Oncology Research
        • Kontakt:
    • Ontario
      • Hamilton, Ontario, Kanada, L8V 5C2
        • Rekrutierung
        • Juravinski Cancer Center
        • Kontakt:
          • SMPA Investigative Site
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrutierung
        • Princess Margaret Cancer Center
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Kanada, H3T 1E2
        • Rekrutierung
        • Jewish General Hospital
        • Kontakt:
          • SMPA Investigative Site
      • Barcelona, Spanien
        • Rekrutierung
        • Hospital Universitario y Politecnico La Fe
        • Kontakt:
          • SMPA Investigative Site
      • Barcelona, Spanien
        • Rekrutierung
        • Institut Catala d'Oncologia
        • Kontakt:
          • SMPA Investigative Site
      • Salamanca, Spanien
        • Rekrutierung
        • Hospital Universitario de Salamanca
        • Kontakt:
          • SMPA Investigative Site
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • Rekrutierung
        • University of Alabama
        • Kontakt:
          • Tiffany Hill
          • Telefonnummer: 205-934-9591
    • Arizona
      • Tucson, Arizona, Vereinigte Staaten, 85724
        • Rekrutierung
        • The University of Arizona Cancer Center
        • Kontakt:
    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • Rekrutierung
        • City of Hope
        • Kontakt:
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Rekrutierung
        • University of Southern California
        • Kontakt:
      • Newport Beach, California, Vereinigte Staaten, 92663
        • Rekrutierung
        • Hoag Family Cancer Institute
        • Kontakt:
    • Colorado
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06510
        • Rekrutierung
        • Yale School of Medicine
        • Kontakt:
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32608
        • Abgeschlossen
        • University of Florida Health Shands Cancer Hospital
      • Miami, Florida, Vereinigte Staaten, 33136
        • Rekrutierung
        • University of Miami
        • Kontakt:
      • Miami, Florida, Vereinigte Staaten, 33176
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21201
        • Rekrutierung
        • University of Maryland
        • Kontakt:
          • Maria Baer, MD
          • Telefonnummer: 410-328-8708
          • E-Mail: mbaer@umm.edu
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Rekrutierung
        • Massachusetts General Hospital
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Rekrutierung
        • University of Michigan
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55455
        • Rekrutierung
        • University of Minnesota
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Rekrutierung
        • Washington University of Medicine
        • Kontakt:
    • New Jersey
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
        • Rekrutierung
        • John Theurer Cancer Center at Hackensack University Medical Center
        • Kontakt:
    • New York
      • Buffalo, New York, Vereinigte Staaten, 14263
        • Abgeschlossen
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, Vereinigte Staaten, 10065
        • Rekrutierung
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
      • New York, New York, Vereinigte Staaten, 10029
      • New York, New York, Vereinigte Staaten, 10065
        • Rekrutierung
        • Weill Cornell Medical Center
        • Kontakt:
      • The Bronx, New York, Vereinigte Staaten, 10461
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27710
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43210
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29425
        • Rekrutierung
        • Medical University of South Carolina
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Rekrutierung
        • Vanderbilt University
        • Kontakt:
          • SMPA Investigative Site
      • Nashville, Tennessee, Vereinigte Staaten, 37203
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77054
        • Rekrutierung
        • MD Anderson Cancer Center
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84112
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22903
        • Rekrutierung
        • University of Virginia Cancer Center
        • Kontakt:
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98109
        • Rekrutierung
        • University of Washington - Fred Hutchinson Cancer Center
        • Kontakt:
      • Lincoln, Vereinigtes Königreich
        • Rekrutierung
        • Lincoln County Hospital
        • Kontakt:
          • SMPA Investigative Site
      • Lincoln, Vereinigtes Königreich
        • Rekrutierung
        • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
        • Kontakt:
          • SMPA Investigative Site
      • London, Vereinigtes Königreich
        • Rekrutierung
        • University College London Hospital's NHS foundation Trust
        • Kontakt:
          • SMPA Investigative Site
      • Oxford, Vereinigtes Königreich
        • Rekrutierung
        • Oxford University Hospitals NHS Foundation
        • Kontakt:
          • SMPA Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
  • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
  • Fulfill the following clinical laboratory parameters:
  • Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
  • ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5%
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
  • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
  • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
  • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
  • Fulfills the following clinical laboratory parameters:
  • Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
  • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
  • Fulfills the following clinical laboratory parameters:
  • Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
  • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
  • Prior allogeneic stem cell transplant within the last 6 months.
  • Eligible for allogeneic bone marrow or stem cell transplantation.
  • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
  • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
  • Corrected QT interval > 480msec.
  • Prior or concurrent malignancy that could interfere with the investigational regime.
  • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
  • Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
  • Pregnant or breastfeeding
  • Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
  • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy
  • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
  • Splenic irradiation within 6 months prior to screening or prior splenectomy
  • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • Presence of Grade ≥ 2 peripheral neuropathy
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm 1: Nuvisertib (TP-3654)

Oral PIM Inhibitor

Andere Namen:
  • TP-3654
Experimental: Arm 2: Nuvisertib (TP-3654) zusätzlich zu Ruxolitinib

Oral PIM Inhibitor

Andere Namen:
  • TP-3654

Oral JAK inhibitor

Andere Namen:
  • Jakafi
Experimental: Arm 3: Nuvisertib (TP-3654) in Kombination mit Momelotinib

Oral PIM Inhibitor

Andere Namen:
  • TP-3654

Oral JAK inhibitor

Andere Namen:
  • Ojjaara

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Determine the incidence of dose-limiting toxicities (DLTs)
Zeitfenster: 28 days

Number of participants with DLTs

28 days
Determine the incidence of treatment emergent adverse events
Zeitfenster: From start of treatment to end of study

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

From start of treatment to end of study
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Zeitfenster: From start of treatment to end of study

Number of participants with ≥ 35% spleen volume reduction (SVR35)

From start of treatment to end of study

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of participants achieving objective response by IWG-MRT response criteria
Zeitfenster: From start of treatment to end of study

Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.

From start of treatment to end of study
Number of participants who have ≥ 25% spleen volume reduction
Zeitfenster: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.

Number of participants who have ≥ 25% spleen volume reduction compared to baseline

Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Zeitfenster: 24 weeks

Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.

24 weeks
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Zeitfenster: After 24 weeks of treatment to end of study

Change in PGIC score

After 24 weeks of treatment to end of study
Determine the incidence of QT interval changes
Zeitfenster: 25 hours

Changes in QT interval and heart rhythm

25 hours
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours

The estimate of time for the nuvisertib concentration or amount to be reduced by half

24 hours
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours

The amount of drug exposure over 24 hours period after administration

24 hours
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours

The maximum nuvisertib concentration after administration

24 hours
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours

The time to reach maximum nuvisertib concentration

24 hours

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anzahl der Patienten mit einer Verringerung der Knochenmarkfibrose
Zeitfenster: Alle 24 Wochen bis zum Ende des Studiums
Alle 24 Wochen bis zum Ende des Studiums
Nuvisertib-Kombinationsarme: Bewerten Sie den Anstieg des Hämoglobins um ≥ 1,5 oder ≥ 2 g/dl gegenüber dem Ausgangswert
Zeitfenster: Vom Beginn der Behandlung bis zum Ende des Studiums
Vom Beginn der Behandlung bis zum Ende des Studiums
Nuvisertib-Kombinationsarme: Beurteilung des Unabhängigkeitsstatus der Erythrozytentransfusion oder etwaiger Anforderungsänderungen
Zeitfenster: Vom Beginn der Behandlung bis zum Ende des Studiums
Vom Beginn der Behandlung bis zum Ende des Studiums
Nuvisertib -Monotherapie: Veränderungen der Thrombozytenzahl im Laufe der Zeit bei Patienten mit Thrombozytzahl <100 x 10^9/l
Zeitfenster: Von Beginn der Behandlung bis zum Ende der Studie
Von Beginn der Behandlung bis zum Ende der Studie
Study potential pharmacodynamic (PD) markers of nuvisertib
Zeitfenster: 12 months

Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.

12 months
Establish overall survival
Zeitfenster: From start of treatment to end of study

The time interval from treatment start date to date of death from any cause

From start of treatment to end of study

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

16. Dezember 2019

Primärer Abschluss (Geschätzt)

30. April 2027

Studienabschluss (Geschätzt)

30. April 2030

Studienanmeldedaten

Zuerst eingereicht

8. November 2019

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. November 2019

Zuerst gepostet (Tatsächlich)

25. November 2019

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren